Compound Monograph
Homoeriodictyol
Homoeriodictyol is a yerba santa flavanone best known as a natural bitter-masking flavor ingredient — its sodium salt suppresses the bitterness of caffeine, quinine and many drugs by antagonizing human bitter taste receptors. It is the 3'-O-methyl ether of eriodictyol and a positional isomer of hesperetin; its therapeutic data are thin and preclinical, with no trials of the isolate.
Sources · 1
Where Does It Come From?
Homoeriodictyol is a naturally occurring flavonoid (flavanone), found in Yerba Santa. It is well tolerated orally (low toxicity).
Concentration
Content by Source
Concentrations not reported. No percent-dry-weight or mg/g figures have been published for this compound in its source plants.
Homoeriodictyol at a Glance
Homoeriodictyol is a yerba santa flavanone with an unusual commercial role: it is a natural bitter-masking flavour ingredient.
Its sodium salt suppresses the bitterness of caffeine, quinine and many drugs by antagonising human bitter taste receptors — a genuinely pharmacological mechanism applied to a food-technology problem, and used industrially to make bitter actives palatable.
That is what the compound is for; it has no therapeutic use of its own.
What It's Used For
Homoeriodictyol is a yerba santa flavanone — the 3’-O-methyl ether of eriodictyol and a positional isomer of hesperetin — and its honest identity is a flavor ingredient, not a therapeutic. Its real fame (and the reason it is a commercial compound at all) is bitter-masking: the sodium salt suppresses the bitterness of caffeine, quinine, salicin and many pharmaceuticals by antagonizing human bitter taste receptors 1,
It is a genuine yerba-santa leaf constituent (~26–61 mg/g in one cultivated analysis 8Reference 8Chemical composition of Eriodictyon californicum (California yerba santa) cultivated in Ontario, Oregon, USAView study →) and part of the historical chemopreventive fraction 7Reference 7Isolation of potential cancer-chemopreventive agents from Eriodictyon californicumView study →.
Its scattered therapeutic signals are thin and preclinical, and one confusion is worth heading off — the potent neuroprotective yerba-santa flavanone is sterubin (a positional isomer, methylated on the A-ring so it keeps the intact catechol B-ring), not homoeriodictyol.
Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. Note the top application is a flavor claim, not a health claim.
The headline and only robustly supported use. In the founding evaluation of bitter-masking flavanones from yerba santa, homoeriodictyol (especially its sodium salt) suppressed the bitterness of caffeine, quinine, salicin and pharmaceuticals in trained sensory panels 1Reference 1Evaluation of bitter-masking flavanones from Herba Santa (Eriodictyon californicum)View study →; the mechanism is antagonism of human bitter taste receptors (hTAS2Rs) 2Reference 2In-vitro evaluation of flavonoids from Eriodictyon californicum for antagonist activity against bitter taste receptorsView study →; and it is used as a bitterness suppressor in model beverages 3Reference 3Optimising the orosensory properties of model functional beverages (homoeriodictyol-Na bitterness suppression)View study → and reduced chemotherapy-associated bitterness in a patient mouthwash study 9Reference 9Clinical trialA homoeriodictyol-sodium mouthwash reduces bitterness sensitivity in patients with gynecological cancer receiving chemotherapyView study →.
Gap: bitter-masking is a perceptual effect — it implies no systemic pharmacology and no disease-modifying benefit 1Reference 1Evaluation of bitter-masking flavanones from Herba Santa (Eriodictyon californicum)View study →.
In two randomized cross-over human interventions, oral homoeriodictyol modulated appetite via bitter-taste signaling 4Reference 4RCTAppetite-inducing effects of homoeriodictyol: two randomised cross-over interventionsView study →, and it has been used as a bitter-receptor antagonist tool to block caffeine-induced gastric acid secretion in parietal cells 5Reference 5Caffeine induces gastric acid secretion via bitter-taste signalling in gastric parietal cells (homoeriodictyol as hTAS2R antagonist)View study →.
Gap: these are taste-physiology studies (the compound as a bitter-receptor ligand), with small n and sensory-metabolic endpoints, not a therapeutic indication 4,
In one mouse study, eriodictyol and homoeriodictyol improved amyloid-β(25–35)-induced memory impairment by inhibiting the NLRP3 inflammasome 6Reference 6AnimalEriodictyol and homoeriodictyol improve memory impairment in Aβ(25–35)-induced mice by inhibiting the NLRP3 inflammasomeView study →.
Gap: a single rodent study at high dose, with no replication and no human data — and the potent neuro-activity in yerba santa belongs to sterubin, not homoeriodictyol 6Reference 6AnimalEriodictyol and homoeriodictyol improve memory impairment in Aβ(25–35)-induced mice by inhibiting the NLRP3 inflammasomeView study →.
Mechanisms
| Target / pathway | Effect | Relevant to |
|---|---|---|
| Human bitter taste receptors (hTAS2Rs) | antagonism → suppressed bitter perception (the signature mechanism) | bitter-masking / flavor |
| Extra-oral hTAS2R signaling (gastric parietal cells) | bitter-receptor antagonist blocks caffeine-triggered gastric acid | gastric/appetite sensory physiology |
| NLRP3 inflammasome | inhibition (single Aβ mouse study) | anti-inflammatory / neuroprotective (thin) |
| Radical scavenging (phenolic B-ring) | generic flavanone antioxidant (class-inferred, in vitro) | antioxidant |
Only the hTAS2R bitter-receptor antagonism is robustly and specifically established; the rest is single-study or class-inferred.
Pharmacokinetics
Homoeriodictyol is a flavanone aglycone with poor oral bioavailability expected (low solubility, extensive phase-II conjugation and rapid first-pass metabolism, as for its hesperetin/eriodictyol congeners); no dedicated human pharmacokinetic study exists. Crucially, as a flavor ingredient it acts locally in the oral cavity and GI lumen on taste receptors, so systemic absorption is largely irrelevant to its headline use.
Clinical trials
There are no therapeutic-isolate clinical trials. The only human studies are sensory/flavor, not therapeutic: two randomized cross-over appetite/bitter-signaling interventions 4Reference 4RCTAppetite-inducing effects of homoeriodictyol: two randomised cross-over interventionsView study →, a homoeriodictyol-sodium mouthwash reducing chemotherapy-associated bitterness 9Reference 9Clinical trialA homoeriodictyol-sodium mouthwash reduces bitterness sensitivity in patients with gynecological cancer receiving chemotherapyView study →, and beverage orosensory optimization 3Reference 3Optimising the orosensory properties of model functional beverages (homoeriodictyol-Na bitterness suppression)View study → — all to be read as flavor/sensory work, never as evidence of therapeutic efficacy.
| Completed | Planned | Terminated | Preclinical / sensory |
|---|---|---|---|
| —(no therapeutic isolate trial) | — | — | Flavor/sensory human + thin preclinical |
Last checked: July 2026.
Toxicity & Safety
Homoeriodictyol is used as a food-flavor ingredient and is well tolerated at the flavor-relevant doses it is actually used at — which is also the limit of what has been studied.
- Well tolerated as a flavor ingredient. Human sensory studies — mouthwash, beverages, appetite trials — report no serious toxicity signal.
- Avoid isolated supplements in pregnancy and lactation. No reproductive data.
- High-dose chronic exposure is uncharacterized. Safety data stop at flavor-level use.
Full Safety & Interactions Detail
Homoeriodictyol (as its sodium salt) is used as a natural bitter-masking food-flavor ingredient and is regarded as GRAS-adjacent; human sensory studies (mouthwash, beverages, appetite trials) report it as well tolerated at flavor-relevant doses 1,
Dosage
There is no established therapeutic dose — there is no therapeutic use to dose for. As a flavor ingredient, the sodium salt is used at low ppm masking concentrations in foods and beverages, determined empirically by sensory panels 1,
References
- Ley JP, et al. (2005). Evaluation of bitter-masking flavanones from Herba Santa (Eriodictyon californicum). Journal of Agricultural and Food Chemistry. https://pubmed.ncbi.nlm.nih.gov/16028996/
- Fletcher JN, et al. (2011). In-vitro evaluation of flavonoids from Eriodictyon californicum for antagonist activity against bitter taste receptors. Journal of Agricultural and Food Chemistry. https://pubmed.ncbi.nlm.nih.gov/22059530/
- Gaudette NJ, Pickering GJ (2012). Optimising the orosensory properties of model functional beverages (homoeriodictyol-Na bitterness suppression). Journal of Food Science. https://pubmed.ncbi.nlm.nih.gov/22582876/
- Hochkogler CM, et al. (2017). Appetite-inducing effects of homoeriodictyol: two randomised cross-over interventions. Molecular Nutrition & Food Research. https://pubmed.ncbi.nlm.nih.gov/28834253/
- Liszt KI, et al. (2017). Caffeine induces gastric acid secretion via bitter-taste signalling in gastric parietal cells (homoeriodictyol as hTAS2R antagonist). Proceedings of the National Academy of Sciences. https://pubmed.ncbi.nlm.nih.gov/28696284/
- Guo P, et al. (2022). Eriodictyol and homoeriodictyol improve memory impairment in Aβ(25–35)-induced mice by inhibiting the NLRP3 inflammasome. Molecules. https://pubmed.ncbi.nlm.nih.gov/35458684/
- Liu YL, et al. (1992). Isolation of potential cancer-chemopreventive agents from Eriodictyon californicum. Journal of Natural Products. https://pubmed.ncbi.nlm.nih.gov/1593282/
- Shock CC, et al. (2026). Chemical composition of Eriodictyon californicum (California yerba santa) cultivated in Ontario, Oregon, USA. Molecules. https://pubmed.ncbi.nlm.nih.gov/42076034/
- Zehentner S, et al. (2026). A homoeriodictyol-sodium mouthwash reduces bitterness sensitivity in patients with gynecological cancer receiving chemotherapy. Scientific Reports. https://pubmed.ncbi.nlm.nih.gov/42230681/
